HIV-1 drug resistance tests may be useful tools for optimizing ART regimens when used in the context of information about viral load, immune and clinical status, adherence practices and available treatment options. Several types of drug resistance tests are available, either as commercial kits or based on published methods for in-house assays. The target product profile for HIV drug resistance tests in low- and middle-income countries: Africa is designed to guide the development of new HIV drug resistance tests in the era of dolutegravir-based antiretroviral therapy (ART) and to facilitate the evaluation of the suitability of currently available HIV drug resistance tests for specific applications. The target product profiles focus on the new-term future for available ART regimens and their use and anticipates an innovate test that will meet the projected demand.
Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.
“Bill Foege takes us inside the world's greatest public health triumph: the eradication of smallpox. It's a story of true determination, passion and courage. The story of smallpox should encourage all of us to continue the critical work of worldwide disease eradication.”--Bill Gates, Co-Chair of the Bill & Melinda Gates Foundation “Bill Foege is one of the public health giants of our times. He was responsible for the design of the campaign that eradicated smallpox—the most important global health achievement in history and possibly the greatest feat in any field of international cooperation. His insights into the nature of this major event will undoubtedly help to meet the global health challenges of the 21st century.”—Julio Frenk, M.D, PhD, Dean, Harvard School of Public Health “The eradication of a disease has long been the holy grail of global health and Bill Foege found it: more than any other person, he was responsible for the eradication of smallpox from the face of the earth. This is a story told by a remarkably humble man, about the extraordinary coalition that he helped to build, and the most impressive global health accomplishment the world has ever seen.”—Mark Rosenberg, author of Real Collaboration: What It Takes for Global Health to Succeed “I am thrilled that Bill Foege, one of the great heroes of the smallpox eradication campaign, has written this important book. It tells a beautiful human story of an incredible public health triumph, and is full of lessons that could be applied to many of the global challenges we face today.”—Helene D. Gayle MD, President and CEO, CARE USA “Bill Foege’s House on Fire is the first-hand account of how a revised strategy to eradicate smallpox was tested, validated, and applied. Without the global adoption of this new surveillance strategy, the final deathblow to this longtime global menace might never have been dealt.”—Adetokunbo O. Lucas, MD, DSc, author of It Was The Best of Times: From Local to Global Health “Smallpox is the most devastating disease the world has known, as it destroyed lives and shaped history over the centuries. House on Fire provides a day-to-day account by my friend Dr. Bill Foege of the battle required to defeat this wily and diabolic virus."--President Jimmy Carter
The emergence of extensively drug-resistant strains of tuberculosis, especially in countries with a high prevalence of human immunodeficiency virus, is a serious threat to global public health and jeopardizes efforts to effectively control the disease. This publication offers updated recommendations for the diagnosis and management of drug-resistant tuberculosis in a variety of geographical, economic and social settings, and the recording of data that enables the monitoring and evaluation of programs.--Publisher's description.
This Open Access volume provides in-depth analysis of the wide range of ethical issues associated with drug-resistant infectious diseases. Antimicrobial resistance (AMR) is widely recognized to be one of the greatest threats to global public health in coming decades; and it has thus become a major topic of discussion among leading bioethicists and scholars from related disciplines including economics, epidemiology, law, and political theory. Topics covered in this volume include responsible use of antimicrobials; control of multi-resistant hospital-acquired infections; privacy and data collection; antibiotic use in childhood and at the end of life; agricultural and veterinary sources of resistance; resistant HIV, tuberculosis, and malaria; mandatory treatment; and trade-offs between current and future generations. As the first book focused on ethical issues associated with drug resistance, it makes a timely contribution to debates regarding practice and policy that are of crucial importance to global public health in the 21st century.
While many volumes have been written about various aspects of antimicrobial resistance, this book is a comprehensive reference work. All manifestations of resistance are addressed: viral; bacterial, parasitical and fungal are given dedicated sections. The underlining molecular mechanisms, which depend not only on the microbe but on the specific drug (target), are highly diverse. This work discusses and compares the biological, biochemical and structural aspects of resistance and its evolution.
